Harnessing hope: how Grace Science used Almac Adapt™ to deliver for children living with NGLY1 Deficiency

On February 28, 2024, eleven years to the day after Grace was diagnosed with NGLY1 Deficiency, the first patient received GS‑100, sparking new hope across the community.

GS-100 is an incredibly high-value therapy for one of the rarest diseases known to science. It needs to be administered during brain surgery. Because of this, the drug needed to be delivered within a precise timeframe, aligned with the surgical procedure.

With Almac Adapt™ accelerating dosing in half the usual time, every shipment has since arrived with zero product loss, zero temperature deviations, and flawless coordination across US clinical sites. This partnership remains united around one mission: delivering life‑changing therapies safely, reliably, and with deep care for the families behind every order. Read more about this journey in our full case study